Filter Results:
(4,685)
Show Results For
- All HBS Web
(4,685)
- People (16)
- News (1,872)
- Research (2,252)
- Events (2)
- Multimedia (221)
- Faculty Publications (1,839)
Show Results For
- All HBS Web
(4,685)
- People (16)
- News (1,872)
- Research (2,252)
- Events (2)
- Multimedia (221)
- Faculty Publications (1,839)
- June 1999 (Revised May 2001)
- Case
CardioThoracic Systems
CardioThoracic Systems, a company that has developed a new system for performing heart surgery on a beating heart, is facing marketing challenges. Discusses the numerous reasons for the system's low penetration (including existing techniques, surgeon resistance, and a... View Details
Keywords: Problems and Challenges; Technological Innovation; Situation or Environment; Marketing Strategy; Sales; Health Care and Treatment; Health Industry; Health Industry; Health Industry; United States
Roberts, Michael J., and Diana S. Gardner. "CardioThoracic Systems." Harvard Business School Case 899-281, June 1999. (Revised May 2001.)
- 17 Jun 2015
- News
Is Small Beautiful?
- 25 Feb 2015
- News
Scholars and Students Unpack the Digital Business Revolution
- 01 Aug 2014
- News
Kaplan Life Sciences Fellows Announced
- 10 Mar 2014
- News
Teaching revolution gathers pace
- 06 Oct 2020
- News
Test Your Board’s Readiness for the Post-Covid Era
- 11 Aug 2020
- News
Your Customers Have Changed. Here's How To Engage Them Again.
- 13 Mar 2020
- News
Remote Everything
- 20 Aug 2020
- Blog Post
Being patients compelled us. Sequoia inspired us. HBS sustained us.
“We better get off this plane ASAP,” Deborah belted out as our plane skittered to a halt at SFO. Deborah re-read the text from our fertility clinic: “We misread your chart. Your sodium levels are dangerously low. Get to a hospital soon. This could be life... View Details
- Working Paper
Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S.
By: Pragya Kakani, Michael Chernew and Amitabh Chandra
Rising list prices are often used to illustrate the burden of prescription drug spending, but payers routinely negotiate rebates from manufacturers that generate differences between list and net prices. List prices are easily available and affect patient cost-sharing,... View Details
Keywords: Pharmaceuticals; Rebates; Health Care and Treatment; Markets; Price; Analysis; Pharmaceutical Industry
Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S." NBER Working Paper Series, No. 26846, March 2020.
- 30 Sep 2020
- News
How Nonprofit Foundations Can Sustainably Fund Disease Research
- 12 Dec 2018
- News
Impact Investing Could Accelerate the Fight Against Cancer
- 04 Oct 2018
- News
Precision medicine needs a business mindset in order to flourish
- 15 Dec 2017
- News
Patient-Powered Precision
- Web
Research in Action - Alumni
the origins of his research interests and taxation in a global context. Action Research to Put Health Care Ideas into Practice Professor Emeritus Robert Kaplan explains his action research, which aims to... View Details
- August 2024
- Article
How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?
By: Leemore S. Dafny, Kate Ho and Edward Kong
Drug copayment coupons to reduce patient cost-sharing have become nearly ubiquitous for high-priced brand-name prescription drugs. Medicare bans such coupons on the grounds that they are kickbacks that induce utilization, but they are commonly used by... View Details
Keywords: Prescription Drugs; Coupons; Impact; Health Care and Treatment; Markets; Price; Spending; Pharmaceutical Industry; United States
Dafny, Leemore S., Kate Ho, and Edward Kong. "How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?" American Economic Journal: Economic Policy 16, no. 3 (August 2024): 314–346.
- April 2017
- Supplement
Imprimis (B)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A). It describes the company’s decision to enter into the pharmaceutical compounding business in 2013–2014. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients’... View Details
Keywords: Healthcare; Drug Compounding; Drug Development; Pharmaceuticals; Small Business; Decision-making, Business Model; Mark Baum; Imprimis; Decision Making; Strategy; Health Care and Treatment; Policy; Pharmaceutical Industry; United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (B)." Harvard Business School Supplement 717-496, April 2017.